SI-Bone (NASDAQ:SIBN) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.
This table compares SI-Bone and Alphatec’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for SI-Bone and Alphatec, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SI-Bone presently has a consensus target price of $24.75, indicating a potential upside of 28.30%. Alphatec has a consensus target price of $6.67, indicating a potential upside of 21.43%. Given SI-Bone’s higher possible upside, equities analysts plainly believe SI-Bone is more favorable than Alphatec.
Institutional and Insider Ownership
45.5% of SI-Bone shares are owned by institutional investors. Comparatively, 19.6% of Alphatec shares are owned by institutional investors. 38.8% of SI-Bone shares are owned by company insiders. Comparatively, 34.3% of Alphatec shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares SI-Bone and Alphatec’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|SI-Bone||$55.38 million||8.56||-$17.45 million||($0.71)||-27.17|
|Alphatec||$91.69 million||3.59||-$28.98 million||($0.58)||-9.47|
SI-Bone has higher earnings, but lower revenue than Alphatec. SI-Bone is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.
SI-Bone beats Alphatec on 8 of the 12 factors compared between the two stocks.
SI-Bone Company Profile
SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Alphatec Company Profile
Alphatec Holdings, Inc., a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures. The company offers MIS products consisting of Battalion Lateral Spacer System and Squadron Lateral Retractor, Illico Minimally Invasive Surgery System, and BridgePoint Spinous Process Fixation System; and fixation products, such as Arsenal Screw System and Zodiac Spinal Fixation Systems. It also provides cervical and cervico-thoracic products, including Trestle Luxe Anterior Cervical Plate System, and Solanas Posterior Cervico/Thoracic Fixation System and Avalon Occipital Plate; and interbody Systems, such as Battalion Universal Spacer System, Novel PEEK and Titanium Spinal Spacers, and Alphatec Solus Locking ALIF Spinal Spacer. In addition, the company offers biologics consisting of AlphaGraft Structural Allograft Spacers, AlphaGraft ProFuse Demineralized Bone Scaffold, Amnioshield Amniotic Tissue Barrier, Alphagraft Demineralized Bone Matrix, and Neocore Osteoconductive Matrix. It sells its products through a network of independent distributors and direct sales representatives in the United States. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.